Ships within 24 hours on business days · +10% with Bank Pay

Bromantane

Shop

Bromantane · Research brief

Bromantane (Ladasten): History and Clinical Trial Status

60 WORDS

Short answer

Bromantane (Ladasten) is an adamantane derivative first synthesized in the Soviet Union during the 1980s, developed inside a research category that Soviet pharmacologists called actoprotectors, and later registered as a medicine in Russia under the trade name Ladasten. Its clinical trial status outside that single jurisdiction is close to empty: the compound holds no FDA approval and no European Medicines…

Bromantane (Ladasten) is an adamantane derivative first synthesized in the Soviet Union during the 1980s, developed inside a research category that Soviet pharmacologists called actoprotectors, and later registered as a medicine in Russia under the trade name Ladasten. Its clinical trial status outside that single jurisdiction is close to empty: the compound holds no FDA approval and no European Medicines Agency approval, and public trial registries do not show an active, internationally registered interventional program. Most human data sits in Russian-language journals from the 1990s and 2000s, and most mechanistic data sits in rodent work. Real Peptides supplies bromantane as a research-use-only catalog compound for laboratory work.

What is bromantane and how did its discovery begin?

Bromantane is N-(4-bromophenyl)adamantan-2-amine, a secondary amine in which a brominated phenyl ring is joined to the two position of the rigid adamantane cage. Its molecular formula is C16H20BrN, its molecular weight is approximately 306 g/mol, and it is indexed under CAS 87913-26-6. That structure places it in the same broad chemical family as other adamantane-based compounds that entered pharmacology from the 1960s onward, a family whose best known early members came out of antiviral screening and later found use in neurology. The adamantane cage is lipophilic, metabolically stable at several positions, and crosses biological membranes readily, which is one reason medicinal chemistry groups kept returning to it when they wanted central nervous system exposure from a small, synthetically tractable scaffold.

The discovery record for this particular molecule is thin by modern Western standards, and anyone tracing bromantane history and discovery will notice the gap quickly. The original synthesis and screening reports were published inside the Soviet research system, in journals that were often not indexed in the databases Western researchers use by default, and in a language that remains a barrier for most secondary readers. What survives in accessible review literature is a general account: Soviet medicinal chemistry programs ran large series of substituted adamantane derivatives through animal screening batteries during the 1970s and 1980s, and this bromophenyl aminoadamantane emerged from that series as a candidate of interest because of how it behaved in fatigue, heat and hypoxia models rather than because of a receptor-level hypothesis.

The naming history adds further friction. The compound appears in the literature as bromantan, the direct transliteration from Russian, as bromantane in later English-language writing, and as Ladasten once it acquired a trade designation. Sport-related analytical chemistry papers from the late 1990s often use the first spelling, pharmacology reviews often use the second, and Russian clinical reports often use the third. A database search that uses only one of those three strings will miss most of the record, which is part of why the evidence base looks even sparser than it is.

Why did Soviet pharmacology create the actoprotector category?

The actoprotector category existed because Soviet applied pharmacology wanted a class of agents that preserved physical and mental work capacity under adverse conditions without the liabilities associated with classical stimulants. The concept, as described in the review of actoprotector pharmacology published in Biomolecules and Therapeutics in 2012 (PMID: 24009833), covers compounds intended to maintain performance during heat, cold, hypoxia, physical exertion and sustained wakefulness, with an emphasis on avoiding the sharp rebound and depletion patterns that follow amphetamine-type agents. That review is the most frequently cited English-language entry point into the category and places bromantane within it alongside other agents developed in the same research tradition.

The framing matters for interpreting everything that follows. Western drug development organizes itself around indications defined by disease classification, and a regulatory submission must name a condition, an endpoint and a population. The actoprotector framing instead organizes itself around a state, namely degraded performance under stress, which does not map cleanly onto any single approved indication in United States or European regulatory practice. A compound developed to that specification therefore carries a body of animal data built on endurance tests, thermal challenge, hypoxia tolerance and operant performance under load, rather than on validated disease endpoints. The literature from that program is internally coherent but structurally mismatched with the evidence packages regulators outside Russia expect.

The applied context was occupational and military as much as medical. Research into agents that sustain work capacity in extreme environments was a recognized priority, and the screening models reflect that priority. Reviews describe testing paradigms built around swimming endurance, running to exhaustion, performance under elevated ambient temperature and recovery after exertion in rodent models. These are reasonable models of fatigue physiology, and they remain in use, but they are exploratory rather than confirmatory, and they do not support claims about human outcomes.

It is also worth separating the category from the compound. Actoprotector is a classification term, not a mechanism, and compounds grouped under it do not share a single pharmacological pathway. Research that cites the category as though it were a mechanistic claim overstates what the term carries. For laboratory purposes the useful content of the label is historical: it tells a researcher which screening models the early data came from and which questions the original program was asking.

What does the name Ladasten designate?

Ladasten is the trade name under which bromantane was later marketed in Russia as a registered medicine. The molecular entity is the same; the designation marks a transition from a research compound carried in a state pharmacology program to a product with a marketing registration in one national system. Published accounts describe that registration arriving in the late 2000s, with the registered scope framed around asthenic conditions, meaning states characterized by persistent fatigue, reduced work capacity and associated complaints rather than a narrowly defined disease.

That registration is the single most consequential fact in the compound's regulatory history, and it is also the most frequently misread. A marketing registration in Russia establishes that a national regulator reviewed a submitted evidence package and permitted marketing within that jurisdiction under its own rules of evidence. It does not establish approval anywhere else, it does not imply that the submitted package would satisfy FDA or European Medicines Agency standards, and it does not create any status in the United States. Several widely circulated secondary summaries blur this distinction by describing the compound as an approved medicine without naming the jurisdiction, which leads readers to assume a regulatory standing the compound does not have outside Russia.

The trade designation also changed how the literature is organized. Papers published before the registration generally use the chemical name, while clinical reports published around and after it frequently use the brand designation in the title. Pharmacology and gene expression studies from the same period sometimes use the brand name even when reporting rodent work, which can mislead a reader into assuming a clinical context that is not present. Careful reading of the methods section, rather than the title, is the only reliable way to tell whether a given report describes animal or human work.

For researchers building a reference list, the practical consequence is that the brand designation, the chemical name and the transliterated spelling all need to be searched, and that the three sets of results overlap only partially. The naming split is also the reason the compound appears simultaneously in three unrelated literatures: Soviet and Russian applied pharmacology, sport doping control analytical chemistry, and a much smaller set of English-language mechanistic reviews. None of those three literatures cites the other two consistently.

How did Olympic doping control shape the compound's reputation?

The compound became known outside Russia primarily through sport. During the 1996 Summer Olympic Games in Atlanta, a number of athletes returned analytical findings for bromantan, and the resulting cases were contested through sport arbitration. Reporting from that period describes arguments over whether the substance was a stimulant, a masking agent that interfered with detection of other substances, or both, and over whether it was properly covered by the prohibited substance rules in force at the time. The cases prompted rapid rule changes, and the compound was subsequently named explicitly in prohibited lists.

It remains prohibited in sport today. The World Anti-Doping Agency Prohibited List includes bromantan among stimulants, which are prohibited in competition, and the listing applies regardless of the form in which the substance was obtained. Any athlete subject to anti-doping rules who returns an analytical finding for the substance faces a rule violation under the applicable code. Researchers who work with sport-related populations, or who supply materials into environments where tested athletes are present, should understand that the listing is unambiguous and has been in place for decades.

The doping episode had two durable effects on the scientific record. First, it generated a body of analytical chemistry work focused on detecting the parent compound and its metabolites in urine, work that was driven by enforcement needs rather than by pharmacological curiosity. Published descriptions of detection windows from that literature indicate that the substance and its metabolites remain measurable for an extended period after exposure, which is consistent with the lipophilic adamantane scaffold and slow clearance, though the precise figures vary across methods and are not reproduced here without a verifiable citation to attach to them.

Second, the episode fixed the compound's Western reputation as a doping agent rather than as a pharmacology research subject. That framing has shaped what gets published, what gets cited and what commercial interest exists. A molecule that is permanently prohibited in regulated sport has no viable performance market, and a molecule known in the West chiefly through an enforcement controversy attracts little sponsor interest for a formal development program. Both of those facts feed directly into the clinical trial picture described below.

What is the current bromantane clinical trial status?

As of 2026, the bromantane clinical trial status can be summarized in three parts: a completed body of Russian clinical work supporting a national registration, no approved program in the United States or the European Union, and no visible active interventional studies in the major public registries. Searches of public registries do not return ongoing registered trials of the compound under its chemical name or its trade designation, and no sponsor has publicly announced a Western development program. The practical reading is that the compound's clinical record is historical and jurisdictionally confined rather than ongoing.

The Russian clinical work that supported registration was conducted in the 1990s and 2000s and published largely in Russian-language clinical journals. Accessible summaries describe controlled and open-label studies in participants characterized by asthenic conditions, with outcome measures drawn from fatigue and asthenia rating scales, clinician-rated global impressions and self-reported functional capacity. Those reports are the basis for the national registration. They are not indexed or reproduced in a form that allows the specific numerical findings to be verified and restated here, so this page describes them qualitatively and attributes them to the Russian clinical literature rather than quoting results that cannot be checked against a citation.

What is absent is equally important. There is no published multi-site Western confirmatory trial, no registered phase program under FDA oversight, no European marketing authorization application in the public record, and no independent replication of the Russian clinical findings by groups outside that system. There is also no publicly available full clinical study report, which means that outside reviewers cannot audit the original data, the randomization procedures, the blinding integrity or the handling of participant withdrawals. For an evidence appraisal, those absences carry as much weight as the positive reports.

A fourth element of the status question concerns pharmacokinetics in humans. Detailed human pharmacokinetic characterization, including absorption, distribution, metabolism and elimination profiling to modern standards, is not available in the accessible English-language literature. Doping control work has produced detection data, but detection windows and pharmacokinetic parameters are not the same thing, and the former cannot substitute for the latter in a development context. Any laboratory planning work with this compound should treat human kinetic behavior as poorly characterized in the public record.

The compound is also absent from the recognized dietary ingredient framework in the United States. It is not an approved drug and it is not a lawful dietary ingredient, which places products that contain it outside both regulatory channels. Research-use-only supply, with documented identity, is the only context in which the material is handled legitimately, and that is the context in which Real Peptides lists it.

What did the Russian clinical program report, and what are its limits?

The accessible accounts of the Russian clinical program describe studies in participants with asthenic conditions in which the active arms were reported to show improvement on fatigue and asthenia rating instruments relative to comparison arms, alongside reports of acceptable tolerability over the study periods. Those are the broad strokes available to a reader working from secondary summaries and abstracts. Because the primary reports cannot be cited here with verifiable identifiers, no effect sizes, response rates, participant counts or statistical values are reproduced on this page.

The methodological limits of that program, as far as they can be assessed from outside, are substantial. Sample sizes described in secondary accounts are modest by the standards of modern confirmatory trials. The studies were conducted within a single national system, which means investigator independence, site diversity and population diversity are all limited. Preregistration of protocols and statistical analysis plans was not standard practice in that setting during the period in question, which removes one of the main safeguards against selective outcome reporting. Blinding procedures and allocation concealment are not described in the accessible summaries in enough detail for assessment.

Endpoint selection is a further concern. Asthenia rating scales and global impression measures are subjective, and they are sensitive to expectation effects in exactly the direction that a mild activating compound would be expected to produce. Without robust blinding, objective performance measures and independent outcome adjudication, the difference between a real pharmacological effect and an expectancy effect is difficult to separate. This is not a criticism unique to this compound; it applies to most of the fatigue and asthenia literature from the same era, including Western work.

Safety characterization is the weakest part of the picture. A national registration implies that the regulator reviewed a safety package, but the accessible literature does not provide a cumulative exposure database, long-term follow-up, or systematic monitoring of outcomes that would matter for a dopaminergic agent used over extended periods. No published post-marketing pharmacovigilance analysis in English is available for review. Researchers should treat the human safety profile as incompletely characterized in the public record rather than as established.

The net assessment is that the clinical record is real but weak: it exists, it supported a registration in one country, and it would not on its own satisfy the evidentiary expectations of regulators that require adequate and well-controlled investigations with auditable data. That assessment is a statement about evidence quality, not a claim that the reported findings are wrong.

What mechanisms does the preclinical literature attribute to the compound?

The mechanistic account most often repeated in reviews is indirect dopaminergic facilitation, specifically an effect on the synthesis side of dopamine handling rather than on vesicular release. The actoprotector review in Biomolecules and Therapeutics (PMID: 24009833) summarizes the pharmacology of this class and describes activating effects in animal performance models alongside behavioral profiles that reviewers characterized as differing from classical stimulant agents. That review is the anchor citation for the mechanistic summary presented here; the primary rodent reports underlying it are largely Russian-language and are described qualitatively.

The synthesis-side hypothesis, as represented in review literature, holds that the compound increases expression of enzymes involved in catecholamine production in specific brain regions, with tyrosine hydroxylase frequently named as the enzyme of interest, and that the downstream result is a modest and gradual increase in dopaminergic tone rather than an acute surge. If accurate, that mechanism would explain several reported features at once: a slow onset measured in hours rather than minutes, an absence of the sharp comedown associated with release-based agents, and a profile that persists across repeated exposure without the rapid tolerance characteristic of indirect releasers. These are plausible inferences, not established facts, and the gene expression work that supports them has not been widely replicated outside its originating system.

A second mechanistic strand concerns anxiety-related behavior. Reviews describe the compound as producing effects in rodent anxiety paradigms in addition to its activating effects, a combination that is unusual because most activating agents are anxiogenic. Proposed explanations in the secondary literature involve interactions with inhibitory neurotransmission, but the primary evidence for any specific receptor-level interaction is limited, and reviews generally present this as an observation in behavioral models rather than as a resolved mechanism. Laboratories interested in this question would be working at the frontier of a thinly populated literature.

A third strand concerns stress physiology and adaptation, consistent with the actoprotector origins. Reported findings in this area involve performance preservation under thermal and hypoxic challenge and effects on markers associated with stress response. These models are informative about whole-animal resilience but say little about receptor pharmacology, and the translation from endurance models in rodents to any human outcome is speculative.

For laboratory planning, the honest summary is that bromantane has a mechanistic story that is coherent, repeated across reviews, and underpowered in primary evidence. In vitro receptor profiling, independent gene expression replication, regional neurochemistry with modern methods and pharmacokinetic characterization in animal models are all open areas where published data is sparse. That gap is the main reason the compound still attracts laboratory interest.

How does it differ from classical stimulants in the published accounts?

The difference most consistently claimed in the literature is temporal and mechanistic: classical stimulants act by increasing synaptic catecholamine availability through release or reuptake blockade, producing rapid onset and clear offset, while this compound is described as acting further upstream on synthesis capacity, producing a slower and flatter profile. Reviews of actoprotector pharmacology present this contrast as the defining feature of the class, and it is the reason the Soviet program treated these agents as a separate category rather than as stimulant variants.

Several practical consequences follow from that claim if it holds. A synthesis-side agent should not deplete presynaptic stores in the way that repeated release-based exposure does, so the rebound fatigue pattern should be absent or reduced. Tolerance development should follow a different curve. Cardiovascular activation, which in classical stimulants follows from peripheral catecholamine effects, should be less pronounced. Reviews report observations broadly consistent with these predictions in animal models, but the comparative data is not drawn from head-to-head human studies, and no such studies appear in the accessible record.

There is also a reported behavioral difference in the direction of anxiety. Classical stimulants reliably increase anxiety-like behavior in rodent paradigms at activating exposures, whereas reviews describe this compound as showing activating and anxiety-reducing effects in the same models. If replicated independently, that dissociation would be scientifically interesting in its own right, because it suggests the activating effect is not simply generalized arousal. The caveat is that rodent anxiety paradigms are sensitive to locomotor confounds, and an agent that increases exploratory movement can score as anxiolytic on measures that use open-area time as a proxy. Resolving that confound requires designs that most of the original work did not use.

It should also be said plainly that the sport regulatory system classifies the compound as a stimulant regardless of these mechanistic distinctions. Anti-doping classification is based on observed performance effects and policy judgment, not on upstream mechanism, so a compound that reaches a stimulant-like outcome through a synthesis pathway is still listed as a stimulant. Researchers sometimes treat the mechanistic distinction as though it carried regulatory weight. It does not.

Finally, the comparison literature is almost entirely descriptive. There is no published systematic review comparing this compound to reference stimulants across standardized endpoints, no meta-analysis, and no shared outcome framework across the available studies. Statements about how it differs should therefore be read as hypotheses drawn from review summaries rather than as established comparative pharmacology.

Why has no Western regulatory pathway opened for this compound?

The simplest answer is that no sponsor has pursued one. Under the Federal Food, Drug, and Cosmetic Act, a new drug cannot be marketed in the United States without an approved application supported by adequate and well-controlled investigations, and the clinical work required to build that package must be conducted under an investigational new drug exemption with FDA oversight. Foreign clinical data can contribute to such a package, but only when it meets applicable standards for conduct, documentation and auditability, and when the data are applicable to the intended population. The existing Russian record, as it appears in the public domain, is unlikely to meet those conditions without substantial new work.

Commercial incentives are the second barrier. The molecule is decades old, composition-of-matter protection from the original period has long expired, and the synthesis is straightforward for a competent organic chemistry group. A sponsor contemplating a full development program would therefore be funding an expensive clinical package for a compound that competitors could manufacture on approval. That economic structure keeps many older molecules out of modern regulatory pipelines regardless of their scientific interest.

The indication problem is third. The condition described in the Russian registration, asthenia, does not correspond to a single recognized indication with validated endpoints and an accepted regulatory precedent in United States or European practice. A sponsor would need to select a defined population, agree endpoints with the regulator and run the program against those endpoints, which effectively means starting the clinical case from the beginning rather than building on the existing record. Combined with the prohibited status in regulated sport, which closes off the performance-adjacent market entirely, the development case is weak.

In the United States the compound is not a controlled substance under federal scheduling, but absence from the schedules is not permission to market it for human use. It is not an approved drug, and it is not a lawful dietary ingredient, so products presenting it for human consumption fall outside both frameworks. Material supplied for laboratory research is a separate category: it is sold for research use only, labeled accordingly, and not intended for human consumption in any form. State rules and institutional policies may impose further requirements on handling and record keeping.

This page is general information, not legal advice; consult a qualified attorney for advice on any specific situation.

What are the main limits of the evidence base in 2026?

The limits fall into five groups: indexing, replication, design, reporting and kinetics. Indexing is the first and most mechanical problem. A large share of the primary literature was published in Russian-language journals, some of which are not indexed in the databases most researchers search, and the three competing names for the compound fragment what is indexed. A literature review that covers only English-language indexed sources will see a fraction of the record and will tend to overweight the two or three accessible review articles.

Replication is the second. The central mechanistic claims trace back to a relatively small group of reports produced within one research system, and independent laboratories elsewhere have not systematically reproduced them. In a field where replication failures are common even for well-funded findings, a mechanism carried by a thin, geographically concentrated literature should be treated as provisional. The same applies to the clinical findings.

Design is the third. The animal work rests on performance and stress models that are exploratory, and the clinical work rests on subjective scales assessed in conditions where blinding integrity cannot be verified from the published record. Neither body of work was built to the standards of preregistration, blinded outcome adjudication and prespecified analysis that current practice expects.

Reporting is the fourth. Full protocols, statistical analysis plans and individual participant data are not publicly available, so external reviewers cannot distinguish between prespecified and post hoc analyses or assess attrition handling. This is a general feature of clinical research from the period and region in question, not a specific allegation about any study.

Kinetics is the fifth and perhaps the most consequential for laboratory planning. Human absorption, metabolism and elimination data to modern standards are not available in accessible sources, metabolite identification outside doping control contexts is limited, and the long detection windows reported in anti-doping work suggest accumulation behavior that has not been characterized pharmacologically in the open literature. Any laboratory model that assumes rapid clearance would be assuming something the public record does not support.

Taken together, these limits mean that the compound sits in an unusual position: it has a registration in one country, a decades-long history, a recognizable mechanistic story and almost no modern, independently verified data. That combination is exactly what makes it a research subject rather than a settled pharmacological entity.

What should a laboratory verify before sourcing this compound?

Identity verification comes first. The material should be confirmed against CAS 87913-26-6 and the molecular formula C16H20BrN before procurement, because adamantane derivatives are numerous and structurally similar names circulate in the small-molecule supply chain. A certificate of analysis for the specific lot, produced by an independent third-party laboratory, is the document that connects a catalog listing to the physical material in the vial. Real Peptides publishes independent third-party certificates of analysis for every batch at /coas/, and the lot identifier on the container should match the certificate on file.

Second, documentation should establish analytical identity and purity testing by appropriate methods for a small molecule rather than relying on a supplier statement alone. Researchers evaluating a source should be able to see which analytical techniques were used, what the lot identifier is and when the testing was performed. A certificate that cannot be matched to the material in hand is not useful for research record keeping, and funding bodies and institutional reviewers increasingly ask for this chain of documentation.

Third, intended use should be recorded correctly from the start. This compound is supplied for laboratory research only. Real Peptides does not provide preparation or use guidance for its catalog compounds, because research-use-only materials are not supplied with human-use instructions of any kind. What a laboratory can reasonably expect from a supplier is identity, documented testing and traceability, and nothing beyond that.

Where measurement education is appropriate, the relevant framework is concentration, expressed as milligrams of compound per milliliter of solvent.

The broader catalog is listed at /shop/, and details about where Real Peptides operates are published at /location/. For this specific compound, the catalog page is /products/bromantane/.

What would a modern research program on this compound need to establish?

A credible modern program would start by rebuilding the preclinical foundation rather than extending the clinical claims. The first requirement is independent receptor and transporter profiling to determine what the molecule actually binds, because the current mechanistic account is inferential and rests on downstream expression findings rather than direct target identification. Broad profiling panels are routine, inexpensive relative to clinical work, and would either support or undercut the synthesis-side hypothesis quickly.

The second requirement is replication of the gene expression findings in independent laboratories using current methods, with regional specificity, appropriate controls and transparent reporting. The claim that the compound increases expression of catecholamine synthesis enzymes is the load-bearing element of the entire mechanistic story, and it has not been verified outside its originating research tradition. A well-powered replication, positive or negative, would be the single most valuable contribution available to this literature.

The third requirement is pharmacokinetic characterization in animal models, including metabolite identification, tissue distribution and elimination behavior over repeated exposure. The long detection windows reported in anti-doping work point to slow clearance, and slow clearance with repeated exposure raises accumulation questions that no accessible study has addressed. Without that data, neither preclinical study design nor any future clinical planning rests on solid ground.

The fourth requirement, only after the preceding three, would be clinical work designed to current standards: preregistered protocols, defined populations, objective as well as subjective endpoints, verified blinding, independent outcome assessment, prespecified analysis plans and published full study reports. That is the package a regulator would expect, and it is a package that does not currently exist for this molecule in any jurisdiction's public record.

None of this is likely to happen without a sponsor, and the commercial logic described earlier makes a sponsor unlikely. The realistic near-term future for the compound is therefore academic and laboratory research: mechanism studies, in vitro profiling, animal model work and analytical chemistry, conducted by groups with their own reasons for interest. That is the context in which research-use-only material has a legitimate role, and it is the only context in which Real Peptides supplies it.

All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.

References

  • The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomolecules and Therapeutics. 2012. PMID: 24009833. pubmed.ncbi.nlm.nih.gov/24009833
  • World Anti-Doping Code International Standard: Prohibited List. World Anti-Doping Agency. www.wada-ama.org/en/prohibited-list
  • Federal Food, Drug, and Cosmetic Act, Section 505 (21 U.S.C. 355), New Drug Applications. FDA. www.fda.gov
  • ClinicalTrials.gov, public registry of clinical studies. National Library of Medicine. clinicaltrials.gov

Questions

It was first synthesized in the Soviet Union during the 1980s, emerging from medicinal chemistry programs that screened large series of adamantane derivatives. The original synthesis and screening reports appeared in Soviet journals with limited international indexing, which is why the discovery record is sparse in English-language databases today.
Ladasten is the trade designation under which the same molecule was later marketed in Russia as a registered medicine, with the registered scope framed around asthenic conditions. The chemical entity is identical to bromantane; only the name differs, which fragments literature searches across three competing spellings and designations.
No. The compound holds no FDA approval and no European Medicines Agency authorization. It is also not a lawful dietary ingredient in the United States, so products presenting it for human consumption fall outside both regulatory channels. Research-use-only laboratory supply with documented identity is a separate category.
Public registry searches do not return active, internationally registered interventional studies of the compound under its chemical name or trade designation. The clinical record is historical: Russian studies conducted in the 1990s and 2000s supported a national registration, and no Western development program has been publicly announced since.
It became widely known after analytical findings at the 1996 Atlanta Olympic Games, which prompted rapid rule changes and explicit listing. The World Anti-Doping Agency Prohibited List now includes it among stimulants, prohibited in competition, regardless of the mechanistic argument that it works upstream of classical stimulants.
Reviews describe indirect dopaminergic facilitation acting on synthesis capacity rather than vesicular release, with tyrosine hydroxylase expression frequently named. The actoprotector review in Biomolecules and Therapeutics, 2012, is the main English-language summary. That account is coherent but rests on a thin, geographically concentrated primary literature awaiting independent replication.
Real Peptides supplies bromantane as a research-use-only catalog compound for laboratory and research settings, not for human consumption. Independent third-party certificates of analysis are published for every batch, and the lot identifier on the container should match the certificate before the material enters any experimental record.
No. Real Peptides does not provide preparation or use guidance, because these are research-use-only materials supplied without human-use instructions. The appropriate measurement framework for bench work is concentration, expressed as milligrams per milliliter, with working solutions described in laboratory terms such as micrograms per assay.
Weak by modern standards. The supporting clinical work was single-country, modest in scale, published largely in Russian, built on subjective rating scales, and not preregistered or independently replicated. Full study reports are unavailable for external audit, and human pharmacokinetic characterization is absent from the accessible literature.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now